European Journal of Gastroenterology & Hepatology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 5, 2025
Aim:
This
study
aimed
to
investigate
the
relationship
between
lung
function
and
metabolic
dysfunction–associated
steatotic
liver
disease
(MASLD),
potential
mediating
role
of
type
2
diabetes.
Methods
Data
from
2007
2012
National
Health
Nutrition
Examination
Survey
were
used.
Logistic
regression
analysis
was
employed
assess
association
parameters
[forced
vital
capacity
(FVC),
forced
expiratory
volume
in
1
s
(FEV
),
FEV
/FVC]
MASLD
prevalence
while
exploring
diabetes
mediation.
Further
analyses
included
linkage
disequilibrium
score
regression,
Mendelian
randomization,
meta-analysis
examine
causal
MASLD,
considering
Results
The
results
showed
that
higher
FVC
levels
associated
with
decreased
risk,
partially
this
relationship.
Genetic
supported
a
link
acting
as
an
intermediary.
However,
no
significant
found
/FVC
MASLD.
Conclusion
identified
playing
partial
role.
EClinicalMedicine,
Journal Year:
2023,
Volume and Issue:
65, P. 102292 - 102292
Published: Oct. 28, 2023
The
various
subcategories
under
the
overarching
term
of
steatotic
liver
disease
(SLD)
have
been
recently
proposed
by
nomenclature
consensus
group
and
endorsed
international
academic
societies.
Our
aim
was
to
investigate
association
between
each
subtype
SLD
incident
cardiovascular
(CVD)
in
a
nationwide
Korean
cohort.
Pharmacological Reviews,
Journal Year:
2024,
Volume and Issue:
76(3), P. 454 - 499
Published: Jan. 30, 2024
Steatotic
liver
disease
(SLD)
displays
a
dynamic
and
complex
phenotype.
Consequently,
the
metabolic
dysfunction-associated
steatotic
(MASLD)/metabolic
steatohepatitis
(MASH)
therapeutic
pipeline
is
expanding
rapidly
in
multiple
directions.
In
parallel,
non-invasive
tools
for
diagnosing
monitoring
responses
to
interventions
are
being
studied,
clinically
feasible
findings
explored
as
primary
outcomes
interventional
trials.
The
realization
that
distinct
subgroups
exist
under
umbrella
of
SLD
should
guide
more
precise
personalized
treatment
recommendations
facilitate
advancements
pharmacotherapeutics.
This
review
summarizes
recent
updates
pathophysiology-based
nomenclature
outlines
both
effective
pharmacotherapeutics
those
MASLD/MASH,
detailing
their
mode
action
current
status
phase
2
3
clinical
Of
extensive
arsenal
MASLD/MASH
pipeline,
several
have
been
rejected,
whereas
other,
mainly
monotherapy
options,
shown
only
marginal
benefits
now
tested
part
combination
therapies,
yet
others
still
development
monotherapies.
Although
successful
drug
candidate
(or
combinations)
remains
elusive,
such
approaches
will
ideally
target
MASH
fibrosis
while
improving
cardiometabolic
risk
factors.
Due
urgent
need
novel
strategies
potential
availability
safety
tolerability
data,
repurposing
existing
approved
drugs
an
appealing
option.
Finally,
it
essential
highlight
and,
by
extension,
MASLD
be
recognized
approached
systemic
affecting
organs,
with
vigorous
implementation
interdisciplinary
coordinated
plans.
Significance
Statement
SLD,
including,
among
others,
MASH,
considered
most
prevalent
chronic
condition
than
one-fourth
global
population.
aims
provide
information
regarding
pathophysiology,
diagnosis,
management
line
guidelines
Collectively,
hoped
provided
furthers
understanding
state
direct
implications
stimulates
additional
research
initiatives.
Gut Microbes,
Journal Year:
2024,
Volume and Issue:
16(1)
Published: Feb. 1, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
the
most
common
chronic
disease,
and
its
prevalence
has
increased
worldwide
in
recent
years.
Additionally,
there
a
close
relationship
between
MASLD
gut
microbiota-derived
metabolites.
However,
mechanisms
of
metabolites
are
still
unclear.
We
demonstrated
decreased
indole-3-propionic
acid
(IPA)
indole-3-acetic
(IAA)
feces
patients
with
hepatic
steatosis
compared
to
healthy
controls.
Here,
IPA
IAA
administration
ameliorated
inflammation
an
animal
model
WD-induced
by
suppressing
NF-κB
signaling
pathway
through
reduction
endotoxin
levels
inactivation
macrophages.
Bifidobacterium
bifidum
metabolizes
tryptophan
produce
IAA,
B.
effectively
prevents
production
IAA.
Our
study
demonstrates
that
derived
from
microbiota
have
novel
preventive
or
therapeutic
potential
for
treatment.
Cells,
Journal Year:
2025,
Volume and Issue:
14(3), P. 221 - 221
Published: Feb. 4, 2025
Cigarette
smoke
(CS),
an
intricate
blend
comprising
over
4000
compounds,
induces
abnormal
cellular
reactions
that
harm
multiple
tissues.
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
prevalent
chronic
(CLD),
encompassing
non-alcoholic
(NAFL),
steatohepatitis
(NASH),
cirrhosis,
and
hepatocellular
carcinoma
(HCC).
Recently,
the
term
NAFLD
has
been
changed
to
metabolic
dysfunction-associated
steatotic
(MASLD),
NASH
renamed
(MASH).
A
multitude
of
experiments
have
confirmed
association
between
CS
incidence
progression
MASLD.
However,
specific
signaling
pathways
involved
need
be
updated
with
new
scientific
discoveries.
exposure
can
disrupt
lipid
metabolism,
induce
inflammation
apoptosis,
stimulate
fibrosis
through
promote
Currently,
there
no
officially
approved
efficacious
pharmaceutical
intervention
in
clinical
practice.
Therefore,
lifestyle
modifications
emerged
as
primary
therapeutic
approach
for
managing
Smoking
cessation
application
series
natural
ingredients
shown
ameliorate
pathological
changes
induced
by
CS,
potentially
serving
effective
decelerating
MASLD
development.
This
article
aims
elucidate
which
smoking
promotes
MASLD,
while
summarizing
reversal
factors
identified
recent
studies,
thereby
offering
novel
insights
future
research
on
treatment
Clinical and Molecular Hepatology,
Journal Year:
2024,
Volume and Issue:
30(2), P. 225 - 234
Published: Jan. 24, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
was
recently
proposed
as
an
alternative
concept
to
nonalcoholic
fatty
(NAFLD).
We
aimed
investigate
the
prognosis
of
patients
with
biopsy-confirmed
MASLD
using
data
from
a
multicenter
study.
